Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received second dose of Rabavert vaccine on day eight; Case reference number US-BN-2025-001131 is a spontaneous case report initially received from a pharmacist via agency (reference number: USBAV25-1574) on 30-Jun-2025 and concerns a patient of unspecified age and gender. The patient's relevant medical history and concomitant medications were not provided. On an unspecified date, the patient received the first dose of Rabavert vaccine along with its reconstitution parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route, site of administration for indication pre-exposure prophylaxis. On an unspecified date, eight days after first dose, the patient received second dose of Rabavert vaccine along with its reconstitution parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, route and site of administration (explicitly coded as 'inappropriate schedule of product administration'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Rabavert vaccine. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender received the second dose of Rabavert vaccine for indication pre-exposure prophylaxis on the day 8 after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Rabavert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender received the second dose of Rabavert vaccine for indication pre-exposure prophylaxis on the day 8 after the first dose, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to Rabavert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's relevant medical history and concomitant medications were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.